Keywords
Depression ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

139 Search results.

WHO-5 - WHO (Five) Well-Being Index

- 4/22/18 - 1 form, 1 itemgroup, 5 items, 30 languages
Itemgroup: Over the last two weeks
WHO (Five) Well-Being Index (1998 version) http://www.who-5.org Also called : WHO Five, WHO 5

HADS - Hospital Anxiety and Depression Scale (HADS)

- 11/7/17 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: In the past week
Hospital Anxiety and Depression Scale (HADS) was originally developed by [Zigmond, AS; Snaith, RP (1983). "The hospital anxiety and depression scale". Acta Psychiatrica Scandinavica 67 (6): 361–370] and is commonly used by doctors to determine the levels of anxiety and depression that a patient is experiencing. Also used for routine documentation at the University Hospital Muenster (UKM) see http://en.wikipedia.org/wiki/Hospital_Anxiety_and_Depression_Scale

the Effect of Food on the Pharmacokinetics of a Tablet Formulation - 103268 - Pregnancy Report

- 3/13/19 - 1 form, 4 itemgroups, 48 items, 1 language
Itemgroups: Administrative data, Pregnancy Notification Form, Drug Exposures, information investigator
Study ID: 103268 Clinical Study ID: 103268 Study Title: An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of Two Different Formulations of GSK163090 and the Effect of Food on the Pharmacokinetics of a Tablet Formulation in Healthy Male and Female Volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00536679 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK163090 capsule, fasted/fed Trade Name: N/A Study Indication: Depression; Depressive Disorder and Anxiety Disorders

the Effect of Food on the Pharmacokinetics of a Tablet Formulation - 103268 - Adverse Events

- 3/13/19 - 1 form, 14 itemgroups, 51 items, 1 language
Itemgroups: Administrative data, Serious Adverse Event, SECTION 1, Seriousness, SECTION 3: Demography Data, Document section, Section 5, Relevant Medical Conditions, Other relevant risk factors, Document section Concomitant Medications, Section 9 - Investigational Product, Details of relevant Assessments, SECTION 11 Narrative Remarks, Investigator signature
Study ID: 103268 Clinical Study ID: 103268 Study Title: An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of Two Different Formulations of GSK163090 and the Effect of Food on the Pharmacokinetics of a Tablet Formulation in Healthy Male and Female Volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00536679 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK163090 capsule, fasted/fed Trade Name: N/A Study Indication: Depression; Depressive Disorder and Anxiety Disorders

Eligibility Major Depression NCT01788657

- 1/17/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
iCBT for Depression - Standard Versus Condensed Treatment Material; ODM derived from: https://clinicaltrials.gov/show/NCT01788657

Eligibility Internet-based Treatment for Depression NCT02148354

- 1/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Internet Delivered Intervention Program for the Prevention and Treatment of Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02148354

Eligibility Insomnia NCT01663844

- 1/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
New Clinical Applications for Internet-based Cognitive Behavior Therapy for Insomnia and Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01663844

Eligibility Depression NCT02378272

- 1/16/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Care Manager - Coordinating Care for Person Centered Management of Depression in Primary Care; ODM derived from: https://clinicaltrials.gov/show/NCT02378272

Eligibility Depression NCT02359266

- 1/16/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Vitamin D Improves Depression in Liver Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02359266

Eligibility Depression NCT01880814

- 1/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Using SMART Experimental Design to Personalize Treatment for Child Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01880814

Eligibility Depression NCT01488058

- 1/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cognitive Bias Modification (CBM) and Internet Cognitive Behavioural Therapy (iCBT) for Depression- A Randomised Controlled Trial; ODM derived from: https://clinicaltrials.gov/show/NCT01488058

Eligibility Depression NCT01370304

- 1/16/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder; ODM derived from: https://clinicaltrials.gov/show/NCT01370304